- Home
- KALV vs SLI Comparison
KALV vs SLI Comparison
Compare KALV & SLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- SLI
- Stock Information
- Founded
- KALV N/A
- SLI 1998
- Country
- KALV United States
- SLI Canada
- Employees
- KALV N/A
- SLI N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- SLI Major Chemicals
- Sector
- KALV Health Care
- SLI Industrials
- Exchange
- KALV Nasdaq
- SLI Nasdaq
- Market Cap
- KALV 796.4M
- SLI 595.8M
- IPO Year
- KALV N/A
- SLI N/A
- Fundamental
- Price
- KALV $14.01
- SLI $2.91
- Analyst Decision
- KALV Strong Buy
- SLI Buy
- Analyst Count
- KALV 8
- SLI 2
- Target Price
- KALV $26.43
- SLI $3.58
- AVG Volume (30 Days)
- KALV 1.0M
- SLI 1.5M
- Earning Date
- KALV 09-11-2025
- SLI 11-11-2025
- Dividend Yield
- KALV N/A
- SLI N/A
- EPS Growth
- KALV N/A
- SLI N/A
- EPS
- KALV N/A
- SLI N/A
- Revenue
- KALV $1,426,000.00
- SLI N/A
- Revenue This Year
- KALV N/A
- SLI N/A
- Revenue Next Year
- KALV $221.95
- SLI N/A
- P/E Ratio
- KALV N/A
- SLI N/A
- Revenue Growth
- KALV N/A
- SLI N/A
- 52 Week Low
- KALV $7.30
- SLI $1.08
- 52 Week High
- KALV $17.28
- SLI $3.13
- Technical
- Relative Strength Index (RSI)
- KALV 48.69
- SLI 55.51
- Support Level
- KALV $13.26
- SLI $2.77
- Resistance Level
- KALV $17.28
- SLI $3.11
- Average True Range (ATR)
- KALV 1.00
- SLI 0.15
- MACD
- KALV 0.08
- SLI -0.02
- Stochastic Oscillator
- KALV 25.34
- SLI 43.59
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.